These loss-of-function RAD50 mutations could restrict MRE11-mediated degradation of nascent DNA at challenged replication forks in PARP-resistant, BRCA1/2-PALB2-mutated cells, and may help to explain tumor chemoresistance. The gene discussed is PALB2; the disease is neoplasm.